1. Home
  2. LCTX vs SSP Comparison

LCTX vs SSP Comparison

Compare LCTX & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$4.66

Market Cap

395.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
SSP
Founded
1990
1878
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
395.2M
IPO Year
N/A
1988

Fundamental Metrics

Financial Performance
Metric
LCTX
SSP
Price
$1.69
$4.66
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$4.25
$5.50
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,816,000.00
$2,318,706,000.00
Revenue This Year
$5.24
N/A
Revenue Next Year
$126.78
$9.11
P/E Ratio
N/A
N/A
Revenue Growth
24.05
N/A
52 Week Low
$0.37
$1.36
52 Week High
$2.09
$4.98

Technical Indicators

Market Signals
Indicator
LCTX
SSP
Relative Strength Index (RSI) 46.72 60.17
Support Level $1.65 $4.27
Resistance Level $1.82 $4.98
Average True Range (ATR) 0.08 0.35
MACD 0.00 -0.05
Stochastic Oscillator 48.00 67.88

Price Performance

Historical Comparison
LCTX
SSP

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: